Norstella

Citeline Podcasts

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Vizitează neapărat site-ul podcastului și susține-i creatorul: www.citeline.com

Autor

Norstella

Categorie

Business

Site-ul podcastului

www.citeline.com

Cel mai nou episod

19 nov. 2026

Unde asculți?

Podcasturi în aplicație Replaio Radio În curând

Podcasturile ajung în curând în aplicație. Instaleaz-o acum și fii primul care descoperă o abordare complet nouă a podcasturilor

Descarcă din Google Play Instalează gratuit Android 10 mil.+ descărcări · nota 4,7+ iOS în curând

Episoade

Strategic Intent: The Rise Of Mid-Cap Dealmakers 17.08.2026

Biopharma’s small-to-mid-cap players are stepping up as serious acquirers. David Wild and Scrip’s Jessica Merrill unpack how companies like argenx, Insmed, Jazz, Genmab, UCB, and BioMarin are using M&A to extend growth beyond their first commercial successes and what that shift means for investors, dealmaking, and the next generation of big biotechs.

Building The GLP-1 Companion Category, With Beverley Law And Martina Gripp 17.08.2026

Everyone in consumer health is talking about GLP-1s. While this new generation of weight loss drugs is firmly on the prescription-only side, industry is now thinking about how it can meet users’ needs for products that address side effects and the nutritional gaps that come with rapid weight loss. In this episode of HBW Insight’s Over the Counter, ALL Creative founder Beverley Law and consultant M...

Drug Fix: Understanding The PDUFA VIII Revenue Cut And GDUFA IV Name Change 14.08.2026

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the important provisions of the new prescription drug and generic drug user fee commitment letters (:53), including the revenue cut coming in PDUFA VIII (7:16), as well as the new formal meeting names (13:53) and “America First” incentives (23:47) in GDUFA IV. More On These Topics From T...

The State of Play in Biotech and the Decisions Shaping the Industry 12.08.2026

Biotech leaders are navigating disciplined growth, shifting global dynamics, and rising expectations across boards, partners, and clinical teams. In this opening episode, a panel of experienced biotech executives step back to discuss where the industry truly stands, the forces shaping decision‑making, and how leaders are approaching strategy, execution, and collaboration in today’s biotech landsca...

Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA Strategies 11.08.2026

On this episode of Strategic Intent, In Vivo’s David Wild sits down with Doug Love, President and CEO of Annexon Inc., to discuss how the company is transitioning from a platform-centric biotech into a commercial organization. Love walks through the distinct go-to-market strategies for an acute rare disease treated in hospitals versus a large chronic ophthalmology market served by retina practices...

Drug Fix: Regulatory Nationalism And US FDA’s IND Reforms 07.08.2026

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the impact of nationalism on the regulatory process, which entered the fray once again when news of a potential AstraZeneca-Bristol Myers Squibb merger broke (:58), as well as the US Food and Drug Administration’s IND reform pilot program (11:22), including the potentially influential ro...

Proof of Concept - AI in Drug Discovery 06.08.2026

In this episode of Proof of Concept, Krishna Bulusu joins us for an honest, industry-wide look at what AI and simulation can and can't do. Having spent years in oncology data science at AstraZeneca before becoming VP of Product Innovation & Strategy at Turbine, he's seen the problem from both sides — as the big-pharma adopter deciding whether to trust these tools, and as the builder creating them....

Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS Deal 06.08.2026

Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.

Podcast: China's Evolving Role in Global Clinical Development 04.08.2026

How shifting perceptions and new opportunities are changing the way sponsors approach China

Off-Patent, On Record: View Through The Journalist's Lens With Generics Bulletin's Dave Wallace 04.08.2026

Generics Bulletin’s senior reporter Urtė Fultinavičiūtė launches a new interview podcast series “Off-Patent, On Record.” In the inaugural episode, Urtė is joined by Dave Wallace, executive editor at Generics Bulletin, who has been covering the off-patent drug industry as a journalist and editor for 16 years.

Realising Growth Through Pharmacy, With Simon-Kucher’s Christian Danelund And Chris Rebholz 03.08.2026

Consumers are turning to AI at the start of the self-care journey in growing numbers, but they do not yet trust it, the latest Better Health Report from Simon-Kucher & Partners shows. They do trust pharmacists, who can convert that trust into sales, providing crucial sales volume growth for their consumer healthcare industry partners. However, as Simon-Kucher’s Christian Danelund and Chris Rebholz...

European Biotech At A Crossroads: How Can It Stay Competitive? Video Podcast 22.07.2026

This Scrip video podcast brings together three European biotech leaders to discuss the challenges facing the sector, and what measures are needed to stop it falling behind the US and China and to create the next generation of European biotech champions.

The Next Era Of Oncology Biosimilars 22.07.2026

Oncology biosimilars have already helped expand access to established biologic treatments while supporting more sustainable healthcare spending. As the market moves towards increasingly complex therapies, however, identifying viable opportunities will require more than monitoring patent expiries. In this podcast, ICON experts Colin Farquharson and Martin Lachs, discuss how scientific innovation, e...

How ElevateBio Is Betting On Every Gene Editing Modality At Once 21.07.2026

On the heels of Eli Lilly recently committing $3.3bn across two recombinase-focused deals, the question for the field is which gene editing modality, and which delivery system, will get large genetic payloads safely into the right cells. ElevateBio's chief scientific officer Amy Pooler joins In Vivo's David Wild to argue that the answer isn't one technology, but many. In this episode, Pooler walks...

The Generics Bulletin Podcast: Summer Conferences 20.07.2026

Generics Bulletin's editorial team discusses the recent Medicines for Europe legal and annual conferences, attended by executive editor Dave Wallace, as well as the Medicines UK conference attended by reporter Anabel Costa-Ferreira.

Drug Fix: US FDA Undoes Podium Policy, Lessons From CDC, ASPR Confirmation Hearings 17.07.2026

Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the impact of the US Food and Drug Administration clarifying that journal articles written by former commissioner Martin Makary and others were not official guidance (:58). They also discuss the questions an FDA commissioner nominee could field from Senato...

Eisai Video Interview AT AAIC Alzheimer's Conference, July 15 17.07.2026

Eisai's Michael Irizarry talks to Scrip about broadening Leqembi's use with its subcutaneous version, its ongoing Phase III in treating patients before dementia symptoms appear and news from a Phase II study of it tau-targeting asset, etalanetug.

Scrip Deals Podcast, July 2026, with Dr. Bruce Leuchter 16.07.2026

On the July 2026 edition of the Scrip Deals Podcast, Scrip Senior Writer Joseph Haas and Bruce Leuchter, CEO of Neurvati Biosciences and GRIN Therapeutics, discussed the recent trend of biopharma M&A deals valued at $1bn or greater closing quickly. Recent research showed that closing time for such deals is less than half of how long it took to close a billion-dollar acquisition during the span on...

The Dos And Don’ts Of Health Literacy, With Self-Care Forum’s Trevor Gore 14.07.2026

Health literacy is a phrase you hear a lot in consumer health at the moment, but it's not always clear what people mean by it, or what a company is actually supposed to do about it. In this episode of Over the Counter, HBW Insight talks to Trevor Gore, a trustee of the Self-Care Forum who spent more than two decades at Reckitt and now looks at healthcare through behavioural science. Gore's argumen...

Drug Fix: New Complete Response Letter, DTC Ad Regulations And A Potential US FDA Reorg 10.07.2026

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the implications of potential regulations that would cement the FDA’s presumption that it can release complete response letters (:49) and effectively ban direct-to-consumer advertising (18:45), as well as a potential reorganization to create a senior FDA position in charge of all medica...

Tonix’s Bet On Monoclonal Prevention Of Lyme Disease 03.07.2026

Lyme disease is spreading, the last US vaccine was withdrawn in 2002, and the most recent attempt at a new one (Pfizer and Valneva's Phase III candidate) missed its primary endpoint earlier this year. Into that gap steps Tonix Pharmaceuticals with a different idea entirely: skip the vaccine and deliver the antibody directly.   In Vivo's David Wild talks to Tonix CEO Seth Lederman about TNX-4800, a...

Patient Capital And Regulatory Resolve: Dr Reddy’s Chief On Building India's Innovation Backbone 02.07.2026

In this podcast, Satish Reddy, chairman of Dr. Reddy's Laboratories, talks about deploying generic Revlimid gains strategically, building a diversified growth engine, what India must fix — regulatory science, risk capital and more — to become a serious innovation force, and learnings from China. A quick update for our listeners: Scrip now has its own dedicated podcast channel on Spotify and Apple...

China’s New Data Protection Framework: Periods And Impact 02.07.2026

In this episode of the China biopharma English-language podcast, Xu Hu talks about China’s drug regulator finalizing trial data protection measures for drugs registered in the country, and some of the impacts these may have on future licensing deals involving the China market and company strategies in managing product lifecycle and market access in China. Here are links to the stories this episode...

The Economic and Social Value Of Probiotics, With IPA Europe’s Rosanna Pecere 29.06.2026

The science around the microbiome is moving fast, consumers are clearly interested, and yet the category still runs into some long-standing problems in the European Union, not least the inconsistent way the word “probiotic” itself is treated across the region. In this episode of HBW Insight’s Over the Counter podcast, we talk to Rosanna Pecere, Executive Director of IPA Europe, the European office...

‘빅 드럭’ 시대 본격화…글로벌 제약 매출, 2조 달러 넘을 듯 (Korean-language podcast) June 29, 2026 29.06.2026

비만 치료제 시장의 급성장과 일라이 릴리의 티르제파티드가 주도하는 가운데, 이벨류에이트(Evaluate)의 2026 월드 프리뷰(World Preview) 보고서에 따르면 제약 업계는 향후 몇 년 동안 새로운 매출 기록을 경신할 전망입니다(AI 기반 텍스트 음성 변환 및 음성 모방 도구의 도움을 받아 제작되었습니다) https://insights.citeline.com/scrip/market-intelligence/top-drugs/pharma-sales-to-top-2-trillion-as-the-big-drug-er...

Ascultă podcastul Citeline Podcasts în Replaio

Radio și podcasturi într-o singură aplicație - gratuit și fără înregistrare. Instaleaz-o azi și nu rata lansarea

Descarcă din Google Play

Replaio nu este editorul podcasturilor; numele emisiunilor, coperțile și materialul audio aparțin autorilor lor și sunt distribuite prin fluxuri RSS publice